Effect of Statin Use on Influenza Vaccine Effectiveness

Journal of Infectious Diseases

Volumn 214, Issue 8, 2016, Pages 1150-1158

  McLean, Huong Q ^a   Chow, Brian D W ^a   Vanwormer, Jeffrey J ^a   King, Jennifer P ^a   Belongia, Edward A ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Influenza; Influenza vaccine; Statin; Vaccine effectiveness

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLUENZA VACCINE; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

2009 H1N1 INFLUENZA; ACUTE RESPIRATORY TRACT DISEASE; ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; INFECTION RISK; INFLUENZA A (H3N2); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; DRUG INTERACTION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; PROCEDURES; SEASON; VACCINATION;

AGED; DRUG INTERACTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; SEASONS; VACCINATION;

EID: 84990946951     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw335     Document Type: Article

References (34)

1. Black S, Nicolay U, Del Giudice G, Rappuoli R. Influence of Statins on Influenza Vaccine Response in Elderly Individuals. J Infect Dis 2016; 213:1224-8.
2. Omer SB, Phadke VK, Bednarczyk RA, Chamberlain AT, Brosseau JL, Orenstein WA. Impact of Statins on Influenza Vaccine Effectiveness Against Medically Attended Acute Respiratory Illness. J Infect Dis 2016; 213:1216-23.
3. VanWormer JJ, Bateman AC, Irving SA, Kieke BA, Shay DK, Belongia EA. Reply to Fedson. J Infect Dis 2014; 209:1301-2.
4. Belongia EA, Kieke BA, Donahue JG, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009; 199:159-67.
5. Belongia EA, Kieke BA, Donahue JG, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine 2011; 29:6558-63.
6. Treanor JJ, Talbot HK, Ohmit SE, et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012; 55:951-9.
7. Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010-2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season. J Infect Dis 2013; 207:1262-9.
8. Ohmit SE, Thompson MG, Petrie JG, et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014; 58:319-27.
9. Gaglani M, Pruszynski J, Murthy K, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis 2016; 213:1546-56.
10. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of selfreported and registry-based influenza vaccination status in a Wisconsin cohort. Vaccine 2009; 27:6546-9.
11. Peissig P, Sirohi E, Berg RL, et al. Construction of atorvastatin dose-response relationships using data from a large population-based DNA biobank. Basic Clin Pharmacol Toxicol 2007; 100:286-8.
12. Miller AW, McCarty CA, Broeckel U, Hytopoulos V, Cross DS. Development of reusable logic for determination of statin exposure-time from electronic health records. J Biomed Inform 2014; 49:206-12.
13. Foppa IM, Haber M, Ferdinands JM, Shay DK. The case test-negative design for studies of the effectiveness of influenza vaccine. Vaccine 2013; 31:3104-9.
14. Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013; 31:2165-8.
15. Flannery B, Zimmerman RK, Gubareva LV, et al. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. J Infect Dis 2016; 214:1010-9.
16. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.
17. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109(21 Suppl 1): II18-26.
18. Bu DX, Griffin G, Lichtman AH. Mechanisms for the anti-inflammatory effects of statins. Curr Opin Lipidol 2011; 22:165-70.
19. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
20. Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. J Infect Dis 2012; 205:13-9.
21. Brett SJ, Myles P, Lim WS, et al. Pre-admission statin use and in-hospital severity of 2009 pandemic influenza A(H1N1) disease. PLoS One 2011; 6:e18120.
22. Fonville JM, Wilks SH, James SL, et al. Antibody landscapes after influenza virus infection or vaccination. Science 2014; 346:996-1000.
23. Gaglani M, Pruszynski J, Murthy K, et al. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. J Infect Dis 2016; 213:1546-56.
24. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
25. McLean HQ, Thompson MG, Sundaram ME, et al. Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 Seasons. Clin Infect Dis 2014; 59:1375-85.
26. Ohmit SE, Petrie JG, Malosh RE, et al. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. J Infect Dis 2016; 213:1229-36.
27. Skowronski DM, Janjua NZ, De Serres G, et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012; 55:332-42.
28. Skowronski DM, Janjua NZ, Sabaiduc S, et al. Influenza A/subtype and B/ lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis 2014; 210:126-37.
29. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 Influenza Vaccine Effectiveness Associated with Mutation in the Egg-Adapted H3N2 Vaccine Strain Not Antigenic Drift in Circulating Viruses. PLoS One 2014; 9: e92153.
30. Skowronski DM, Chambers C, Sabaiduc S, et al. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season. J Infect Dis 2015; 212:726-39.
31. Skowronski DM, Chambers C, Sabaiduc S, et al. A perfect storm: Impact of genomic variation and serial vaccination on low influenza vaccine effectiveness during the 2014-15 season. Clin Infect Dis 2016; 63:21-32.
32. Mosterin Hopping A, McElhaney J, Fonville JM, Powers DC, Beyer WE, Smith DJ. The confounded effects of age and exposure history in response to influenza vaccination. Vaccine 2016; 34:540-6.
33. Lee PY, Scumpia PO, Byars JA, et al. Short-term atorvastatin treatment enhances specific antibody production following tetanus toxoid vaccination in healthy volunteers. Vaccine 2006; 24:4035-40.
34. Packard RR, Schlegel S, Senouf D, et al. Atorvastatin treatment and vaccination efficacy. J Clin Pharmacol 2007; 47:1022-7.